Day 1 – Wednesday September 13
09:00 LSX Welcome Address
Caitlin McNally, Conference Director, LSX
09:10 Keynote Panel: Acquisition A-Game - Strategies For Securing Success
Despite global disruptions and slowdown in IPO and SPAC activity in 2022, the final quarter of the 2022 saw an increase in M&A deal-making in the medtech industry. Whilst not hitting the heights of previous years, industry financing remains robust for the right innovations, and the demographic shift and the growth in the consumer health sector is offering new opportunities for medtech companies. However, competition for funds and opportunities is fierce, making it crucial for medtech companies to develop sound business strategies and position themselves for long-term success. A panel of experienced medtech industry experts will discuss how medtech companies can bolster their M&A and business development strategies in 2024
.png?width=100&height=100&name=MicrosoftTeams-image%20(34).png)
%20Peripheral%20Intervention%2c%20BD.jpeg?width=100&height=100&name=Antonio%20Sanchez-Cordero%2c%20VP%20Business%20Development%20(M%26A)%20Peripheral%20Intervention%2c%20BD.jpeg)
10:20 Morning Break
11:00 Diagnostic Disruption - The Evolving Landscape Of Medtech Diagnostics
The American healthcare system, with among the world’s highest healthcare costs, continually focusses heavily on reactive treatment. With successive and concurrent crises, there is a need more than ever before, for proactive diagnostic and preventative care. With the IVD sector tipped as the largest device area by 2028, coupled with the digital transformation of the industry, the opportunity in this sector is ever-growing. A panel of diagnostic industry leaders discuss how medtech companies can tap into this sectors growth and how to traverse potential obstacles.
11:55 FDA Focus - Steering Clear Of Regulatory Roadblocks
The US medtech industry is a global leader. However, for both domestic and international companies, navigating the complex regulatory landscape in the US can be a significant challenge. With recent changing documentation in the realms of digital health and AI, it is essential that companies stay abreast of changing regulations. A panel of industry regulatory experts discuss how companies can build a robust regulatory strategy.
12:45 Lunch Break
13:45 Global Market Access - The Medtech Maze Across Europe, US, And China
The global medtech market access landscape presents a complex maze for companies to navigate. With globally unique requirements and regulations in a rapidly evolving industry, knowing where to start can be a challenge in itself. A panel of market access leaders discuss the differing paths to market worldwide, their unique challenges and opportunities and how medtech companies can best position themselves to get their product to the payer.
15:30 Afternoon Break
17:40 Drinks Reception
Day 2 – Thursday, September 13
09:00 LSX Welcome Address
09:10 Keynote Panel: Medtech Evolution: Harnessing The Power Of Innovation For A Better Healthcare System
The innovation environment is rapidly evolving and presents a wealth of opportunities for companies to make an impact. With a massive pipeline of technologies, there is an abundance of potential for new and exciting products to be developed. However, with this potential comes challenge, including the need for end-to-end solutions, incorporating the voice of the clinician, and providing not just the product but the training to use it. Even before prototyping, there is a need to consider how hospitals will adopt the product, including buying, storing and reimbursement codes, as well as the explosion of data and the risk of clinician burnout. The industry is at a turning point, and those who can navigate these challenges will be well-positioned to make a real difference in the healthcare system. A panel of industry leaders discuss how medtech companies need to companies can succeed in an increasingly saturated market.
10:00 Fireside Chat: From Conception to Commercialisation - Prioritising People Across the Company Life Cycle
Planning early through company conception, though growth and on the long journey to commercialisation is critical for saving, time, resources and building a robust multi-skilled business. An executive who has built, scaled, commercialised, and exited multiple medtech businesses, discusses the critical talent considerations companies need to make, and when, to reduce bottlenecks and deliver in a competitive landscape.
Joseph Reed, Principal, Accordance Search
Sandy Thompson, Executive Consultant, Ceribell & Chief Commercial Advisor, Petrero
10:20 Morning Break
11:00 Panel: Green And Clean – Why ESG Should Be A Priority
Medtech companies are facing a growing emphasis on Environmental, Social, and Governance (ESG) considerations, as investors and stakeholders look for companies with a strong commitment to sustainability, social responsibility, and ethical practices. However, companies face unique challenges in implementing such policies, when balancing these commitments with regulatory compliance and high R&D costs. Despite these challenges, medtech companies that prioritise ESG considerations can reap benefits such as cost reduction, improved reputation, and talent attraction. As healthcare shifts towards value-based care, companies with strong ESG practices will be well-positioned to meet the needs of health-conscious consumers. A panel of industry leaders discuss why medtech CEO’s should push ESG policies up their priority list.
11:55 CVC Collaboration - Building Winning Partnerships
As the medtech industry continues to evolve and innovation becomes increasingly important, many small and medium-sized medtech companies are turning to corporate venture capital (CVC) as a source of funding and strategic support. CVC allows these companies to tap into the resources and expertise of larger, established players in the industry, while also providing an opportunity for these larger companies to access new technologies and business models. However, for medtech companies, navigating the CVC landscape can be tricky. This panel will bring together industry experts to discuss the role of CVC in the medtech industry and provide insights on what medtech companies need to know in order to be successful in securing CVC funding.
12:50 Lunch Break
14:00 Panel: Chain Reaction - Keeping The Medtech Industry's Supply Chain On Track
Being a sector heavily reliant on complex global supply chains, disrupted by a variety of factors, including natural disasters, geopolitical tensions, and trade disputes, there is pressure for companies to increase their agility. Additionally, as the industry becomes more digitized and data-driven, there is an increased need for secure and reliable data management and communication throughout the supply chain. Industry leaders are now investing in strategies to improve supply chain resilience, such as diversifying suppliers and implementing real-time data analytics. A panel of industry leaders discuss how companies can increase their supply chain resiliency.
14:40 Panel: Designed To Last – Developing Future-Proof Innovations
Although producing essential products and somewhat shielded with what the economy can throw at them, medtech companies are facing an increasingly oversaturated market. Companies need to have data-driven strategies and technologies in place to demonstrate their value to investors, clients, and regulators. These macroeconomic factors coupled with a shifting healthcare system and increasing digital transformation requires companies to shift their thinking on product design and manufacturing to build recurrent revenue streams and ensure true value for their customers. Key leaders in product design and development discuss considerations and potential challenges for companies taking their product off the page and into the market.
15:20 Health Equity – Confronting Racial Bias, Promoting Inclusion And Improving Diversity
Racial bias, lack of inclusion and diversity in the medtech industry is a critical issue that negatively impacts patient care and outcomes. Research in women’s health, and studies inclusive of minority populations has been historically neglected. This is demonstrated in historical lack of funding in these areas, the use of biased data and AI models which inaccurately reflecting the needs and experiences of diverse patient populations. This results in suboptimal care and unequal healthcare outcomes for women and minority populations. Key thought leaders discuss how the current medtech industry is and isn’t addressing health inequities and how medtech companies can bridge the gap.
16:00 Close of Congress
Company Showcases
Day 1 – Wednesday, September 13
Day 2 – Thursday, September 14
Day 1–Wednesday 13 September - 13:45
There’s nothing that comes close to hearing the honest advice and experience of peers treading the same path as you. LSX’s CEO Forums offer executives the chance to exchange ideas with and seek advice from peers in a private group setting. They are an opportunity to share learnings, best practice and some great thinking, as well as meeting other influential people to support your business journey. Capped at 20 participants, the forums operate under strict Chatham House Rule.
13:45 Opening remarks and introductions
Giles Hamilton, International Medtech Executive
13:50 Ahead of the Curve: Proactive People Planning On The Journey To Commercialization
Building, scaling and growing a company towards commercialization requires a myriad of strategic priorities, much of which can never be started soon enough. Building a team boasting the expertise, diverse skills, and a shared vision and mindset is high amongst them. This session explores the importance of a proactive talent strategy on the journey to commercialization.
Jocelyn O'Grady, Partner, Accordance Search
14:10 Q&A
14:20 Forging the Path to Market: Creating Value and Readiness for Medtech Commercialization
Oleg Shikhman, CEO & Founder, Gynion
14:40 Q&A
14:50 Group discussion
15:00 Wrap-up
Day 2- Thursday, September 14th - 11:00am
LSX’s IPO Workshop offers executives the chance to exchange ideas with and seek advice from experts in an interactive group setting. They are an opportunity to unpack key processes, procedures and KSFs to a successful listing and considerations for other routes public.
IPO Workshop: “3 Ps” of Going Public – Preparation, Path, and Post Transaction
For companies, founders, and entrepreneurs considering entrance into the public markets, this session will focus on the “3 Ps” of going public – preparation, path, and post-transaction; and the different ways to go public in challenging markets. Are you and your board prepared? What path is most appropriate for you: traditional or an alternative ‘going public avenue. How can you best prepare for success post-transaction?
John Rudy, Member, Mintz
Co-hosted by:
Day 2- Thursday, September 14th - 2:00pm
LSX’s IP Workshop offers executives the chance to hear from experts and get the right advice and best practice from experts on the critical consideration of IP. The workshop will provide a guide to intellectual property in life sciences and robustly protecting innovation.
Essential Guide to Intellectual Property in Life Sciences Transactions and Protecting Medicines
Chad E. Davis, Ph.D., Partner, Dechert
Hosted by:
.png?width=150&height=84&name=Mediloom%20(1).png)
